Moderna Highlights Encouraging Revaccination Data for Influenza and RSV Vaccines Ahead of Major Regulatory Decisions
Robust Safety and Immunogenicity Found in Revaccination Studies Presented for mRNA-1010 and mRESVIA
Moderna is set to present new findings for two of its leading vaccine programs—mRNA-1010 for seasonal influenza and mRESVIA for RSV—at the 2026 ESCMID Global Congress in Munich. The presentations, focused on revaccination in older adults, underscore both products’ strong safety and immune response profiles, providing investors and clinicians with potential signals for upcoming regulatory milestones.
Key Data: Sequential mRNA Influenza Vaccination Maintains or Improves Immune Response
In an analysis of adults aged 50 and up from multiple Phase 3 studies, participants who received a second dose of mRNA-1010 about 23 months after their first vaccine achieved similar hemagglutination inhibition geometric mean fold rises for all three major WHO-recommended influenza strains (A/H1N1, A/H3N2, B/Victoria). Notably, immune responses were numerically higher than those in participants revaccinated with a traditional egg-based flu vaccine. Importantly, no new safety issues or increases in adverse reactions were observed, supporting the feasibility of periodic mRNA-based flu revaccination in this age group.
| Vaccine | Study Population | Time Between Doses (Months) | Immune Response vs. Comparator | Safety Profile |
|---|---|---|---|---|
| mRNA-1010 | Adults 50+ | 23 | Numerically higher than egg-based vaccines | No new safety concerns; similar adverse reactions |
| mRESVIA (mRNA-1345) | Adults 60+ | Greater than 12 | Protection restored to primary dose levels | No new safety concerns observed |
mRESVIA: Revaccination Restores RSV Protection with Favorable Safety
Interim results from an ongoing Phase 3 trial in adults aged 60+ showed that revaccination with mRESVIA, after an initial protein-based RSV vaccine, was well-tolerated and restored immune protection to levels similar to those seen after the primary dose. Side effects were aligned with past expectations: injection-site pain, minor swelling or redness, mild fatigue, headache, and fever in some cases, but no serious safety signals emerged. These findings could strengthen mRESVIA’s profile versus existing RSV vaccine options and support annual or semi-annual revaccination strategies in vulnerable populations.
Pipeline Momentum Builds Ahead of Regulatory Reviews in 2026
With regulatory submissions for mRNA-1010 under review in the United States, Europe, Canada, and Australia — and more filings planned — Moderna is targeting initial approvals in 2026 pending ongoing reviews. The company will also showcase 13 additional scientific presentations at ESCMID, spanning infectious disease targets from COVID-19 to norovirus, signaling both deep research activity and confidence in its mRNA platform’s breadth.
Key Takeaway: Data Supports Versatility and Tolerability of mRNA Vaccines in Older Adults
These new revaccination data reinforce Moderna’s leadership in mRNA vaccine science, with robust safety and immune results that may influence future vaccination schedules for influenza and RSV. For investors and healthcare professionals, the upcoming regulatory decisions and additional data expected in 2026 will be crucial for assessing the next chapter of vaccine innovation in older and high-risk adults.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI